Development of a Broad-Spectrum Antiviral Agent with Activity Against Herpesvirus Replication and Gene Expression

Abstract

Purpose: To evaluate the broad-spectrum antiviral activity of peptide H9 (H9) in vitro in order to gain insight into its underlying molecular mechanisms. Method: Antiviral activity against Herpes simplex virus type 1 (HSV-1) was determined using thiazolyl blue (MTT) assay. Polymerase Chain Reaction (PCR) was employed to assay H9 antiviral activity against human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV). The inhibitory effect of H9 on the replication of these viral genes including early genes was assayed by real time-Ppolymerase chain reaction (RT-PCR) and Western blot. Results: H9 possessed significant inhibitory effect on the four different herpesviruses with 50 % inhibitory concentration (IC50) of 1.21 ng/mL (HSV-1). AD169 infection was strongly inhibited with an

Hyperjaponol H, A New Bioactive Filicinic Acid-Based Meroterpenoid from Hypericum japonicum Thunb. ex Murray

“…EBV is generally linked to a group of autoimmune ailments, such as systemic lupus erythematosus [ 20 ], multiple sclerosis [ 21 ], and rheumatoid arthritis [ 22 ]. Currently, anti-EBV drugs like ganciclovir and aciclovir, have efficacy against EBV lytic infections, while the increasing emergence of drug-related toxicity, cross-resistance, and side effects also limit their clinical application [ 23 , 24 , 25 ]. As a successive biochemical research on this herb, compound 1 was carried out an inhibition assay on lytic DNA replication of EBV in B95-8 cells in terms of our previous procedure [ 16 ].…”